• LAST PRICE
    4.4400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.3000/ 5
  • Ask / Lots
    4.7100/ 3
  • Open / Previous Close
    4.5000 / 4.4400
  • Day Range
    Low 4.3700
    High 4.6100
  • 52 Week Range
    Low 2.9400
    High 20.4800
  • Volume
    486,249
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 4.44
TimeVolumeYMAB
09:32 ET98574.5599
09:35 ET10434.525
09:37 ET5094.6
09:39 ET1004.61
09:42 ET11774.53
09:44 ET2944.55
09:46 ET11004.55
09:48 ET10874.55
09:50 ET28484.54
09:51 ET2004.5346
09:55 ET6004.51
09:57 ET1004.53
10:04 ET3004.4934
10:06 ET4004.51
10:08 ET85514.53
10:11 ET17024.525
10:13 ET1004.52
10:18 ET5004.5001
10:20 ET43084.45
10:22 ET85564.47
10:26 ET78364.43
10:27 ET6034.42
10:29 ET19294.4
10:31 ET43094.4
10:33 ET6004.4
10:36 ET1004.4
10:38 ET4004.4
10:40 ET13004.395
10:42 ET3004.395
10:44 ET8194.39
10:45 ET40004.4
10:47 ET43494.39
10:49 ET2004.39
10:54 ET33104.4
10:56 ET37564.39
10:58 ET11004.4
11:00 ET6004.4
11:02 ET16754.4
11:03 ET17964.4
11:05 ET65414.39
11:07 ET42004.42
11:09 ET19544.4
11:12 ET103984.4
11:16 ET27244.39
11:18 ET7124.4
11:20 ET30004.405
11:21 ET76484.41
11:23 ET17004.405
11:27 ET4004.4
11:30 ET28744.4
11:32 ET2004.4
11:34 ET43254.4
11:36 ET7044.4
11:52 ET1004.395
11:56 ET46964.4
11:57 ET25004.4
11:59 ET113834.41
12:03 ET1004.41
12:06 ET10214.44
12:08 ET201004.4
12:12 ET46074.39
12:14 ET4004.395
12:15 ET20994.4
12:17 ET6004.385
12:19 ET11164.38
12:21 ET12004.38
12:26 ET2004.385
12:28 ET15304.39
12:30 ET13124.4
12:32 ET306344.42
12:33 ET23084.46
12:35 ET1004.465
12:37 ET13654.47
12:39 ET6004.47
12:46 ET13724.47
12:48 ET4004.48
12:53 ET717324.54
12:55 ET24424.5301
12:57 ET6004.51
01:00 ET2004.495
01:04 ET6004.495
01:06 ET14684.475
01:11 ET33704.46
01:13 ET7004.46
01:15 ET1004.45
01:18 ET10854.47
01:27 ET14494.46
01:31 ET8944.44
01:33 ET8004.42
01:36 ET21474.4
01:38 ET3004.42
01:40 ET5264.43
01:44 ET3004.42
01:45 ET3004.42
01:47 ET10704.43
01:51 ET4004.425
01:54 ET7954.4234
01:58 ET3004.425
02:00 ET1004.43
02:03 ET11924.43
02:05 ET1004.43
02:07 ET31504.43
02:09 ET2004.43
02:12 ET15914.4
02:14 ET13004.4
02:16 ET3004.41
02:18 ET1004.41
02:23 ET26744.4
02:30 ET2004.4
02:34 ET4004.4
02:36 ET6004.41
02:38 ET37594.41
02:39 ET1004.43
02:41 ET4004.42
02:43 ET2004.415
02:45 ET16944.43
02:48 ET3004.42
02:50 ET2004.41
02:52 ET16414.42
02:57 ET13904.44
02:59 ET7004.45
03:01 ET1004.44
03:03 ET5254.4573
03:10 ET3244.46
03:12 ET4244.47
03:14 ET6244.46
03:15 ET2004.46
03:17 ET1004.46
03:19 ET4004.46
03:21 ET10254.445
03:26 ET4504.4474
03:28 ET4004.45
03:30 ET8414.45
03:32 ET4004.44
03:33 ET2004.455
03:35 ET9004.46
03:37 ET5004.47
03:39 ET3244.47
03:42 ET50174.455
03:44 ET2674.455
03:46 ET4494.455
03:48 ET39384.44
03:51 ET42514.44
03:53 ET6004.435
03:55 ET46044.43
03:57 ET42304.45
04:00 ET322104.44
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesYMAB
Y-mAbs Therapeutics Inc
193.9M
-1.5x
---
United StatesKMPH
KemPharm Inc
190.1M
-5.3x
---
United StatesIKNA
Ikena Oncology Inc
162.4M
-3.0x
---
United StatesAFMD
Affimed NV
176.6M
-2.1x
---
United StatesSTTK
Shattuck Labs Inc
157.3M
-2.5x
---
United StatesXOMA
XOMA Corp
238.7M
60.2x
---
As of 2023-01-31

Company Information

Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. It is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Contact Information

Headquarters
230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
Phone
212-847-9841
Fax
302-655-5049

Executives

Independent Chairman of the Board
James Healy
President, Interim Chief Executive Officer, Founder, Director, Head of Business Development and Strategy
Thomas Gad
Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Bo Kruse
Chief Operating Officer, Senior Vice President
Joris Wilms
Senior Vice President, Chief Technical Officer
Torben Lund-Hansen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$193.9M
Revenue (TTM)
$43.4M
Shares Outstanding
43.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.69
EPS
$-3.06
Book Value
$4.12
P/E Ratio
-1.5x
Price/Sales (TTM)
4.5
Price/Cash Flow (TTM)
---
Operating Margin
-298.07%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.